Mucormycosis - resurgence of a deadly opportunist during COVID-19 pandemic : Four case reports
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved..
BACKGROUND: Coronavirus disease 2019 (COVID-19) patients who suffer severe infection or comorbidities have an increased risk of developing fungal infections. There is a possibility that such infections are missed or misdiagnosed, in which case patients may suffer higher morbidity and mortality. COVID-19 infection, aggressive management strategies and comorbidities like diabetes render patients prone to opportunistic fungal infections. Mucormycosis is one of the opportunistic fungal infections that may affect treated COVID patients.
CASE SUMMARY: We present a case series of four adult males who were diagnosed with mucormycosis post-COVID-19 recovery. All the patients had diabetes and a history of systemic corticosteroids for treatment of COVID-19. The mean duration between diagnosis of COVID-19 and development of symptoms of mucor was 15.5 ± 14.5 (7-30) d. All patients underwent debridement and were started on antifungal therapy. One patient was referred to a higher center for further management, but the others responded well to treatment and showed signs of improvement at the last follow-up.
CONCLUSION: Early diagnosis and management of mucormycosis with appropriate and aggressive antifungals and surgical debridement can improve survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
World journal of clinical cases - 9(2021), 36 vom: 26. Dez., Seite 11338-11345 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Upadhyay, Shalini [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 co-infection |
|---|
| Anmerkungen: |
Date Revised 25.01.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.12998/wjcc.v9.i36.11338 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336061218 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336061218 | ||
| 003 | DE-627 | ||
| 005 | 20231225231258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12998/wjcc.v9.i36.11338 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336061218 | ||
| 035 | |a (NLM)35071564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Upadhyay, Shalini |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mucormycosis - resurgence of a deadly opportunist during COVID-19 pandemic |b Four case reports |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Coronavirus disease 2019 (COVID-19) patients who suffer severe infection or comorbidities have an increased risk of developing fungal infections. There is a possibility that such infections are missed or misdiagnosed, in which case patients may suffer higher morbidity and mortality. COVID-19 infection, aggressive management strategies and comorbidities like diabetes render patients prone to opportunistic fungal infections. Mucormycosis is one of the opportunistic fungal infections that may affect treated COVID patients | ||
| 520 | |a CASE SUMMARY: We present a case series of four adult males who were diagnosed with mucormycosis post-COVID-19 recovery. All the patients had diabetes and a history of systemic corticosteroids for treatment of COVID-19. The mean duration between diagnosis of COVID-19 and development of symptoms of mucor was 15.5 ± 14.5 (7-30) d. All patients underwent debridement and were started on antifungal therapy. One patient was referred to a higher center for further management, but the others responded well to treatment and showed signs of improvement at the last follow-up | ||
| 520 | |a CONCLUSION: Early diagnosis and management of mucormycosis with appropriate and aggressive antifungals and surgical debridement can improve survival | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID-19 co-infection | |
| 650 | 4 | |a Case report | |
| 650 | 4 | |a Case series | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Fungal infection | |
| 650 | 4 | |a Zygomycetes | |
| 700 | 1 | |a Bharara, Tanisha |e verfasserin |4 aut | |
| 700 | 1 | |a Khandait, Manisha |e verfasserin |4 aut | |
| 700 | 1 | |a Chawdhry, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Bharat Bhushan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of clinical cases |d 2013 |g 9(2021), 36 vom: 26. Dez., Seite 11338-11345 |w (DE-627)NLM233331727 |x 2307-8960 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:36 |g day:26 |g month:12 |g pages:11338-11345 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12998/wjcc.v9.i36.11338 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 36 |b 26 |c 12 |h 11338-11345 | ||